Chronic Myelogenous Leukaemia


Patient participation in clinical research

Dr Gianantonio Rosti

At the 20th Congress of the European Hematology Association (EHA), Dr Gianantonio Rosti of the University of Bologna, Italy, explains the importance of engaging patients in cancer treatment. In patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors (TKIs), there is a need for interventions to address any adverse effects on quality of life.

See all videos from: